The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Anlotinib combined with nab-paclitaxel and cisplatin as neoadjuvant treatment (NAT) for esophageal squamous cell carcinoma (ESCC): Update results of a single-arm, phase Ⅱ clinical trial.
 
Yan-Feng Zhang
No Relationships to Disclose
 
Xiao-Bing Li
No Relationships to Disclose
 
Yong-Gui Hong
No Relationships to Disclose
 
Xiao-Ming Li
No Relationships to Disclose
 
Wei-Min Liang
No Relationships to Disclose
 
Zhi-Xin Zheng
No Relationships to Disclose
 
Guang-Yi Yang
No Relationships to Disclose
 
Yan-Yan Wen
No Relationships to Disclose
 
Heng Cao
No Relationships to Disclose
 
Wei-Long Wu
No Relationships to Disclose
 
Wen-Zhong Su
No Relationships to Disclose